Sandbox:Cancer screening and primary care
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Vishal Devarkonda, M.B.B.S[2]
Overview
Worldwide, cancer is among the leading causes of morbidity and mortality; cancer contributed to approximately 8.2 million deaths in 2012, or an estimated 13% of overall deaths.[1] WHO expects a 70% increase in the number of new cancer cases over the next two decades.[2] The burden of cancer is substantial and increasing worldwide.[3] The incidence, prevalence, and mortality of specific cancers vary widely across countries as a result of variations in lifestyle risk factors (such as tobacco use, physical inactivity, excess body weight, reproductive patterns), the prevalence of carcinogenic infections (e.g., Hepatitis B, Hepatitis C, HPV), genetics, and the availability of health care resources.[3] In 2012, lung, prostate, colorectal, gastric, and liver carcinomas were the most common cancers among men, while breast, colorectal, lung, cervical, and gastric carcinomas were most common among women.[4] In 2014, the Agency for Healthcare Research and Quality estimated the direct medical costs associated with cancer in United States at $87.7 billion dollars.[5] It is estimated that HBV/HCV and HPV are responsible for up to 20% of cancer deaths in low- and middle-income countries. It is also estimated that more than 30% of these cases are preventable. Measures to prevent some types of cancer include effective screening, vaccination, and lifestyle modifications. This page provides information about the epidemiology and primary care aspects of preventing cancer.
Epidemiology
Worldwide, cancer is among the leading causes of morbidity and mortality; cancer contributed to approximately 8.2 million deaths in 2012, or an estimated 13% of overall deaths.[1] The most common type of cancer (excluding non-melanoma skin cancers) is breast cancer; it is estimated that there were more than 249,000 new cases in the United States in 2016. The next most common cancers are lung cancer and prostate cancer. In the United States, to qualify as a common cancer, the estimated annual incidence for 2016 had to be 40,000 cases or more.
The following table presents official estimates of new cases and deaths in the United States for each common cancer type:[6]
American Cancer Society: Cancer Facts & Figures 2016 | ||
---|---|---|
Cancer Type | Estimated New Cases | Estimated Deaths |
Breast | 249,200 | 40,890 |
Lung (Including Bronchus) | 224,390 | 158,080 |
Prostate | 180,890 | 26,120 |
Colon and Rectal (Combined) | 134,490 | 49,190 |
Bladder | 76,960 | 16,390 |
Melanoma | 76,380 | 10,130 |
Non-Hodgkin Lymphoma | 72,580 | 20,150 |
Thyroid | 64,300 | 1,980 |
Kidney (Renal Cell and Renal Pelvis) Cancer | 62,700 | 14,240 |
Leukemia (All Types) | 60,140 | 24,400 |
Endometrial | 60,050 | 10,470 |
Pancreatic | 53,070 | 41,780 |
Adulthood Cancers
Top 10 Cancer Sites: 2013, Male and Female, Unites States (All Races)[7] | |||
---|---|---|---|
Incidence | Mortality | ||
Cancer type | Incidence | Cancer type | Mortality |
Female Breast | 123.7 | Lung and Bronchus | 43.4 |
Prostate | 101.6 | Female Breast | 20.7 |
Lung and Bronchus | 59.4 | Prostate | 19.2 |
Colon and rectum | 38.4 | Colon and rectum | 14.5 |
Corpus and Uterus | 25.9 | Pancreas | 10.8 |
Melanomas of the Skin | 20.7 | Ovary | 7.2 |
Urinary Bladder | 20.0 | Leukemias | 6.7 |
Non-Hodgkin Lymphoma | 18.5 | Liver and Intrahepatic Bile duct | 6.5 |
Kidney and Renal Pelvis | 16.0 | Non-Hodgkin Lymphoma | 5.7 |
Thyroid | 14.6 | Corpus and Uterus | 4.6 |
* Rates are per 100,000 persons and are age-adjusted to the 2000 U.S. standard population.
Most Common Cancers in the United States by Gender[8] | |||||||
---|---|---|---|---|---|---|---|
Male | Female | ||||||
Most Common (by Occurrence) | Incidence | Most Common (by Mortality) [9] | Mortality | Most Common (by Occurrence) | Incidence | Most Common (by Mortality) [9] | Mortality |
Prostate cancer | 101.6 | Lung cancer | 53.9 | Breast cancer | 123.7 | Lung cancer | 35.4 |
Lung cancer | 69.8 | Prostate cancer | 19.2 | Lung cancer | 51.5 | Breast cancer | 20.7 |
Colorectal cancer | 44.2 | Colorectal cancer | 17.3 | Colorectal cancer | 33.6 | Colorectal cancer | 12.1 |
* Rates are per 100,000 persons and are age-adjusted to the 2000 U.S. standard population.
Childhood Cancers
In 2013, the most commonly diagnosed cancers and leading causes of cancer-related death in children aged 0 to 19 years were leukemia and central nervous system cancers.[10]
Childhood Cancers | ||||
---|---|---|---|---|
Incidence | Mortality | |||
Cancer type | 0-14 years | 0-19 years | 0-14 years | 0-19 years |
All cancers combined | 16.8 | 18.0 | 2.1 | 2.3 |
Leukemias | 4.8 | 4.3 | 0.6 | 0.6 |
Brain and Central nervous system cancer | 3.6 | 3.2 | 0.7 | 0.7 |
* Rates are per 100,000 persons and are age-adjusted to the 2000 U.S. standard population.
Please click here to know more about the cancer epidemiology
Prevention
Effective measures for cancer prevention include:
- Screening
- Vaccination
- Lifestyle modifications
Screening
Breast Cancer
United States Preventive Services Task Force Recommendations for Breast Cancer Screenings | ||
---|---|---|
Population | Recommendation | Grade |
Women, 40 Years and Older | The USPSTF concludes that the current evidence is insufficient to assess the additional benefits and harms of clinical breast examination (CBE) beyond screening mammography in women 40 years or older. | I |
Women, Age 50-74 Years | The USPSTF recommends biennial screening mammography for women 50-74 years. | B |
Women, Before the Age of 50 Years | The decision to start regular, biennial screening mammography before the age of 50 years should be an individual one and take patient context into account, including the patient's values regarding specific benefits and harms. | C |
Women, 75 Years and Older | The USPSTF concludes that the current evidence is insufficient to assess the benefits and harms of screening mammography in women 75 years and older. | I |
Breast cancer screening relevance
Studies have reported that, for women of all age groups with an average risk, breast cancer screening was associated with a reduction in breast cancer mortality of approximately 20%, although there was an uncertainty in the quantitative estimates of outcomes for different breast cancer screening strategies in the United States.[11]
Please click here to know more about breast cancer screening
Colon cancer
United states preventive services task force recommendations for Colon cancer screening | ||
---|---|---|
Population | Recommendation | Grade |
Adults aged 50 to 75 years | The USPSTF recommends screening for colorectal cancer starting at age 50 years and continuing until age 75 years. | A |
Adults aged 76 to 85 years | The decision to screen for colorectal cancer in adults aged 76 to 85 years should be an individual one, taking into account the patient’s overall health and prior screening history.
|
C |
Colon cancer screening relevance
Studies have reported, 40% to 60% lower risk of incident colorectal cancer and mortality from colorectal cancer after screening colonoscopy.[12]
Please click here to know more about Colon cancer screening.
Cervical cancer
United states preventive services task force recommendations for Cervical cancer screening | ||
---|---|---|
Population | Recommendation | Grade |
Women 21 to 65 (Pap Smear) or 30-65 (in combo with HPV testing) | The USPSTF recommends screening for cervical cancer in women age 21 to 65 years with cytology (Pap smear) every 3 years or, for women age 30 to 65 years who want to lengthen the screening interval, screening with a combination of cytology and human papillomavirus (HPV) testing every 5 years. | A |
Cervical cancer screening relevance
Studies have reported, that in patients undergoing regular cervical cancer, approximately 70%-80% of cervical cancer deaths can be prevented.[13]
Please click here to know more about Cervical cancer screening.
Lung cancer
United states preventive services task force recommendations for Lung cancer screening | ||
---|---|---|
Population | Recommendation | Grade |
Adults Aged 55-80, with a History of Smoking | The USPSTF recommends annual screening for lung cancer with low-dose computed tomography (LDCT) in adults aged 55 to 80 years who have a 30 pack-year smoking history and currently smoke or have quit within the past 15 years. Screening should be discontinued once a person has not smoked for 15 years or develops a health problem that substantially limits life expectancy or the ability or willingness to have curative lung surgery. | B |
Lung caner screening relevance
National lung screen trial (nlst) a randomized controlled trial, involving 50,000 participants as demonstrated a 20% relative lung cancer mortality benefit.[14]
Please click here to know more about Lung cancer screening.
Vaccination
Vaccine | Recommendation | |
---|---|---|
HPV vaccine | Age< 15 years | Two doses of HPV vaccine at least six months apart. |
Age> 15 years |
| |
Hepatitis B vaccine |
|
HPV vaccine relevance in cancer prevention
Studies have reported, that introduction of the 4vHPV vaccine, has decreased the prevalence of HPV 6/11/16/18 cervical/vaginal infections, genital warts, low- and high-grade cytological abnormalities, CIN2, CIN3, and AIS among females in their teens and 20s.[16]
Please click here for know more about HPV vaccine.
Hepatitis B vaccine relevance in cancer prevention
Strong evidence that hepatocellular cancer (HCC) can be prevented is provided by a cluster randomized controlled trial of the immunization of 75,000 newborns with hepatitis B virus (HBV) vaccine. After a median of about 25 years of follow-up, the incidence ratio of primary liver cancer in the vaccination-at-birth group to the control group (68% of whom received catch-up vaccinations at ages 10–14 years) was 0.16 (95% confidence interval, 0.03–0.77).[17] These findings suggest that if HBV can be prevented, then much HCC can be prevented.
Please click here for know more about Hepatitis B vaccine.
Lifestyle modifications
Life style modifications | ||
---|---|---|
Avoiding Tobacco | Cigarette Smoking | Lung cancer is the leading cause of cancer death, and cigarette smoking causes almost all cases. Compared to nonsmokers, current smokers are about 25 times more likely to die from lung cancer. Smoking causes about 80% to 90% of lung cancer deaths. Smoking also causes cancer of the mouth and throat, esophagus, stomach, colon, rectum, liver, pancreas, voicebox (larynx), trachea, bronchus, kidney and renal pelvis, urinary bladder, and cervix, and causes acute myeloid leukemia.[18][19] |
Secondhand Smoke | Adults who are exposed to secondhand smoke at home or at work increase their risk of developing lung cancer by 20% to 30%. Concentrations of many cancer-causing and toxic chemicals are higher in secondhand smoke than in the smoke inhaled by smokers.
Please click here to know more about smoking cessation Please click here to know more about Lung cancer | |
Protecting Your Skin | Skin cancer is the most common kind of cancer in the United States. Exposure to ultraviolet (UV) rays from the sun and tanning beds appears to be the most important environmental factor involved with developing skin cancer. To help prevent skin cancer while still having fun outdoors, protect yourself by seeking shade, applying sunscreen, and wearing sun-protective clothing, a hat, and sunglasses.
Please click here to know more about Skin cancer | |
Limiting Alcohol Intake |
Please click here to know more about alcoholism | |
Keeping a Healthy Weight | Research has shown that being overweight or obese substantially raises a person’s risk of getting endometrial (uterine), breast, prostate, and colorectal cancers. Overweight is defined as a body mass index (BMI) of 25 to 29, and obesity is defined as a BMI of 30 or higher.
Please click here to know more about obesity management | |
Getting Tested for Hepatitis C | Hepatitis is inflammation of the liver, which is most often caused by a virus. In the United States, the most common type of viral hepatitis is Hepatitis C. Over time, chronic Hepatitis C can lead to serious liver problems including liver damage, cirrhosis, liver failure, or liver cancer. CDC recommends that anyone who was born between 1945 and 1965 get tested for Hepatitis C.
Please click here to know more about Hepatitis C |
Please click here to know more about Cancer prevention
References
- ↑ 1.0 1.1 http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx
- ↑ http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx
- ↑ 3.0 3.1 Torre LA, Siegel RL, Ward EM, Jemal A (2016). "Global Cancer Incidence and Mortality Rates and Trends--An Update". Cancer Epidemiol Biomarkers Prev. 25 (1): 16–27. doi:10.1158/1055-9965.EPI-15-0578. PMID 26667886.
- ↑ "Cdc".
- ↑ "Agency of health research and quality".
- ↑ American Cancer Society. Cancer Facts & Figures 2016. Atlanta: American Cancer Society; 2016
- ↑ "United States Cancer Statistics: 1999–2013 Incidence and Mortality Web-based Report. Atlanta (GA): Department of Health and Human Services, Centers for Disease Control and Prevention, and National Cancer Institute; 2016".
- ↑ "U.S. Cancer Statistics Working Group. United States Cancer Statistics: 1999–2013 Incidence and Mortality Web-based Report. Atlanta (GA): Department of Health and Human Services, Centers for Disease Control and Prevention, and National Cancer Institute; 2016".
- ↑ 9.0 9.1 Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, Feuer EJ, Thun MJ (2005). "Cancer statistics, 2005". CA Cancer J Clin. 55 (1): 10–30. PMID 15661684.
- ↑ [www.cdc.gov/uscs. "U.S. Cancer Statistics Working Group. United States Cancer Statistics: 1999–2013 Incidence and Mortality Web-based Report. Atlanta: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute; 2016"] Check
|url=
value (help). - ↑ Myers ER, Moorman P, Gierisch JM, Havrilesky LJ, Grimm LJ, Ghate S; et al. (2015). "Benefits and Harms of Breast Cancer Screening: A Systematic Review". JAMA. 314 (15): 1615–34. doi:10.1001/jama.2015.13183. PMID 26501537. Review in: Ann Intern Med. 2016 Mar 15;164(6):JC26
- ↑ Brenner H, Stock C, Hoffmeister M (2014). "Effect of screening sigmoidoscopy and screening colonoscopy on colorectal cancer incidence and mortality: systematic review and meta-analysis of randomised controlled trials and observational studies". BMJ. 348: g2467. doi:10.1136/bmj.g2467. PMC 3980789. PMID 24922745.
- ↑ Landy R, Pesola F, Castañón A, Sasieni P (2016). "Impact of cervical screening on cervical cancer mortality: estimation using stage-specific results from a nested case-control study". Br J Cancer. 115 (9): 1140–1146. doi:10.1038/bjc.2016.290. PMC 5117785. PMID 27632376.
- ↑ National Lung Screening Trial Research Team. Aberle DR, Adams AM, Berg CD, Black WC, Clapp JD; et al. (2011). "Reduced lung-cancer mortality with low-dose computed tomographic screening". N Engl J Med. 365 (5): 395–409. doi:10.1056/NEJMoa1102873. PMC 4356534. PMID 21714641. Review in: Ann Intern Med. 2011 Nov 15;155(10):JC5-06
- ↑ 15.0 15.1 "Cdc-cancer-prevention vaccination".
- ↑ Garland SM, Kjaer SK, Muñoz N, Block SL, Brown DR, DiNubile MJ; et al. (2016). "Impact and Effectiveness of the Quadrivalent Human Papillomavirus Vaccine: A Systematic Review of 10 Years of Real-world Experience". Clin Infect Dis. 63 (4): 519–27. doi:10.1093/cid/ciw354. PMC 4967609. PMID 27230391.
- ↑ Qu C, Chen T, Fan C, Zhan Q, Wang Y, Lu J; et al. (2014). "Efficacy of neonatal HBV vaccination on liver cancer and other liver diseases over 30-year follow-up of the Qidong hepatitis B intervention study: a cluster randomized controlled trial". PLoS Med. 11 (12): e1001774. doi:10.1371/journal.pmed.1001774. PMC 4280122. PMID 25549238.
- ↑ "U.S. Department of Health and Human Services. The Health Consequences of Smoking—50 Years of Progress: A Report of the Surgeon General, 2014".
- ↑ "International Agency for Research on Cancer. IARC monographs on the evaluation of carcinogenic risks to humans: Volume 100E: Personal Habits and Indoor Combustions. Lyon, France: International Agency for Research on Cancer; 2012".
- ↑ Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F, Bouvard V; et al. (2007). "Carcinogenicity of alcoholic beverages". Lancet Oncol. 8 (4): 292–3. PMID 17431955.